Form 8-K - Current report:
SEC Accession No. 0001213900-24-100368
Filing Date
2024-11-20
Accepted
2024-11-20 08:30:36
Documents
14
Period of Report
2024-11-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0221896-8k_hoth.htm   iXBRL 8-K 29696
2 PRESS RELEASE OF HOTH THERAPEUTICS, INC. DATED NOVEMBER 20, 2024 ea022189601ex99-1_hoth.htm EX-99.1 7615
  Complete submission text file 0001213900-24-100368.txt   217804

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE hoth-20241120.xsd EX-101.SCH 3039
4 XBRL LABEL FILE hoth-20241120_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE hoth-20241120_pre.xml EX-101.PRE 22375
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0221896-8k_hoth_htm.xml XML 3786
Mailing Address 590 MADISON AVENUE 21ST FLOOR NEW YORK NY 10022
Business Address 590 MADISON AVENUE 21ST FLOOR NEW YORK NY 10022 (646)756-2997
Hoth Therapeutics, Inc. (Filer) CIK: 0001711786 (see all company filings)

EIN.: 821553794 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38803 | Film No.: 241478349
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)